Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2025 Vol. 3 > No. 4 > 100165
Next Article Previous Article
COMMENTARY   Open Access     Cite

Harnessing circadian timing to reduce aGVHD: A new paradigm in stem cell transplantation

  • 1.

    Department of Hematology, The First Affiliated Hospital of USTC, National Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

  • 2.

    Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei 230001, China

  • 3.

    Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

More Information
The Innovation Medicine  3(4),  https://doi.org/10.59717/j.xinn-med.2025.100165  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Wang Y., Gao X., Wang T., et al. (2024). Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia. Chin. J. Cancer Res. 36:530−544. DOI:10.21147/j.issn.1000-9604.2024.05.06

    View in Article CrossRef Google Scholar

    [2] Wang C., Lutes L. K., Barnoud C., et al. (2022). The circadian immune system. Sci. Immunol. 7:eabm2465. DOI:10.1126/sciimmunol.abm2465

    View in Article CrossRef Google Scholar

    [3] Hou Y., Wu Y., Cao Y., et al. (2025). Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease. Cell 188:3030−3044.e3017. DOI:10.1016/j.cell.2025.03.022

    View in Article CrossRef Google Scholar

    [4] Wilcken H., Kaier K., Meyer T., et al. (2025). Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: A retrospective analytical cohort study. Bone Marrow Transplant. Online ahead of print. DOI:10.1038/s41409-025-02689-w

    View in Article Google Scholar

    [5] Liu X., Cao L., Wu X., et al. (2024). Vedolizumab provides a new hope of acute graft-versus-host disease prophylaxis through immune regulation. Innov. Med. 2:100083. DOI:10.59717/j.xinn-med.2024.100083

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Wu Y., Hou Y., Zhan C., et al. (2025). Harnessing circadian timing to reduce aGVHD: A new paradigm in stem cell transplantation. The Innovation Medicine 3:100165. https://doi.org/10.59717/j.xinn-med.2025.100165
    Wu Y., Hou Y., Zhan C., et al. (2025). Harnessing circadian timing to reduce aGVHD: A new paradigm in stem cell transplantation. The Innovation Medicine 3:100165. https://doi.org/10.59717/j.xinn-med.2025.100165

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(1322) PDF downloads(832)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.